Latest Insider Transactions at Elevance Health, Inc. (ELV)
This section provides a real-time view of insider transactions for Elevance Health, Inc. (ELV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Elevance Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Elevance Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Grant, award, or other acquisition
|
Direct |
12,008
+21.88%
|
-
|
|
Mar 01
2023
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
607
-5.07%
|
$284,683
$469.03 P/Share
|
|
Mar 01
2023
|
Gail Boudreaux President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
44,297
+12.81%
|
-
|
|
Mar 01
2023
|
Gail Boudreaux President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,471
-2.21%
|
$1,158,899
$469.03 P/Share
|
|
Jan 03
2023
|
Blair Williams Todt EVP, CLO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
3,983
+32.47%
|
-
|
|
Dec 30
2022
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
1,754
-6.17%
|
$898,048
$512.97 P/Share
|
|
Dec 01
2022
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-2.65%
|
$61,425
$525.25 P/Share
|
|
Nov 04
2022
|
Gail Boudreaux President and CEO |
SELL
Bona fide gift
|
Direct |
10,000
-8.24%
|
-
|
|
Nov 01
2022
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
200
-1.64%
|
$108,800
$544.53 P/Share
|
|
Nov 01
2022
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
79
-0.54%
|
$42,976
$544.53 P/Share
|
|
Nov 01
2022
|
Deanna D Strable Soethout Director |
BUY
Grant, award, or other acquisition
|
Direct |
200
+50.0%
|
-
|
|
Jun 09
2022
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Open market or private sale
|
Direct |
6,328
-6.86%
|
$3,094,392
$489.56 P/Share
|
|
Jun 09
2022
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
6,328
+7.66%
|
$1,771,840
$280.62 P/Share
|
|
Jun 06
2022
|
Robert L Dixon Jr Director |
SELL
Open market or private sale
|
Direct |
420
-4.24%
|
$208,740
$497.14 P/Share
|
|
May 19
2022
|
Ramiro G Peru Director |
SELL
Open market or private sale
|
Direct |
990
-9.52%
|
$463,320
$468.88 P/Share
|
|
May 18
2022
|
Robert L Dixon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+4.25%
|
-
|
|
May 18
2022
|
Bahija Jallal Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+11.63%
|
-
|
|
May 18
2022
|
Ryan M. Schneider Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+7.87%
|
-
|
|
May 18
2022
|
Elizabeth E Tallett Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+4.45%
|
-
|
|
May 18
2022
|
R Kerry Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+5.1%
|
-
|
|
May 18
2022
|
Ramiro G Peru Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+4.06%
|
-
|
|
May 18
2022
|
Lewis Hay Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+4.19%
|
-
|
|
May 18
2022
|
Susan D. De Vore Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+33.95%
|
-
|
|
May 18
2022
|
Antonio F Neri Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+11.23%
|
-
|
|
Mar 10
2022
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Open market or private sale
|
Direct |
17,703
-13.37%
|
$8,161,083
$461.16 P/Share
|
|
Mar 10
2022
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Exercise of conversion of derivative security
|
Direct |
1,848
+5.83%
|
$242,088
$131.8 P/Share
|
|
Mar 03
2022
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
2,423
-56.02%
|
$1,121,849
$463.68 P/Share
|
|
Mar 03
2022
|
Ronald W Penczek CAO & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,559
+12.09%
|
$461,464
$296.81 P/Share
|
|
Mar 02
2022
|
Gail Boudreaux President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,645
-1.35%
|
$761,635
$463.49 P/Share
|
|
Mar 02
2022
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
446
-1.54%
|
$206,498
$463.49 P/Share
|
|
Mar 02
2022
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
493
-1.73%
|
$228,259
$463.49 P/Share
|
|
Mar 02
2022
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
110
-0.75%
|
$50,930
$463.49 P/Share
|
|
Mar 02
2022
|
Gloria M Mccarthy EVP & Chief Administrative Off |
SELL
Payment of exercise price or tax liability
|
Direct |
487
-0.8%
|
$225,481
$463.49 P/Share
|
|
Mar 02
2022
|
John E Gallina EVP & Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
1,420
-2.47%
|
-
|
|
Mar 02
2022
|
John E Gallina EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
413
-0.71%
|
$191,219
$463.49 P/Share
|
|
Mar 02
2022
|
Ronald W Penczek CAO & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-1.85%
|
$24,076
$463.49 P/Share
|
|
Mar 01
2022
|
Gail Boudreaux President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
36,498
+13.41%
|
-
|
|
Mar 01
2022
|
Gail Boudreaux President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,352
-15.18%
|
$6,923,752
$451.5 P/Share
|
|
Mar 01
2022
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Grant, award, or other acquisition
|
Direct |
9,196
+14.32%
|
-
|
|
Mar 01
2022
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
3,568
-15.34%
|
$1,609,168
$451.5 P/Share
|
|
Mar 01
2022
|
Blair Williams Todt EVP, CLO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,883
+29.89%
|
-
|
|
Mar 01
2022
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
191
-7.01%
|
$86,141
$451.5 P/Share
|
|
Mar 01
2022
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Grant, award, or other acquisition
|
Direct |
10,465
+16.15%
|
-
|
|
Mar 01
2022
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
4,667
-20.55%
|
$2,104,817
$451.5 P/Share
|
|
Mar 01
2022
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
3,969
+12.75%
|
-
|
|
Mar 01
2022
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
804
-7.01%
|
$362,604
$451.5 P/Share
|
|
Mar 01
2022
|
Gloria M Mccarthy EVP & Chief Administrative Off |
BUY
Grant, award, or other acquisition
|
Direct |
10,465
+7.94%
|
-
|
|
Mar 01
2022
|
Gloria M Mccarthy EVP & Chief Administrative Off |
SELL
Payment of exercise price or tax liability
|
Direct |
4,871
-8.76%
|
$2,196,821
$451.5 P/Share
|
|
Mar 01
2022
|
John E Gallina EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,157
+8.98%
|
-
|
|
Mar 01
2022
|
John E Gallina EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,162
-8.16%
|
$1,877,062
$451.5 P/Share
|